Alaunos Therapeutics (NASDAQ:TCRT) Trading Down 0.5% – Time to Sell?

Posted by Patrick Bannon on Jul 27th, 2026

Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Free Report)’s share price traded down 0.5% during mid-day trading on Monday . The stock traded as low as $1.8522 and last traded at $1.93. Approximately 14,434 shares traded hands during trading, a decline of 9% from the average daily volume of 15,792 shares. The stock had previously closed at $1.94.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded shares of Alaunos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

Get Our Latest Stock Analysis on TCRT

Alaunos Therapeutics Trading Down 0.5%

The firm has a market cap of $47.13 million, a PE ratio of -0.91 and a beta of -1.02. The business has a fifty day moving average price of $2.24 and a 200 day moving average price of $2.66.

Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) last posted its earnings results on Friday, May 15th. The company reported ($0.59) earnings per share for the quarter.

Institutional Trading of Alaunos Therapeutics

A hedge fund recently raised its position in Alaunos Therapeutics stock. Geode Capital Management LLC lifted its stake in shares of Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Free Report) by 25.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,736 shares of the company’s stock after buying an additional 3,945 shares during the quarter. Geode Capital Management LLC owned about 0.85% of Alaunos Therapeutics worth $64,000 at the end of the most recent reporting period. 27.72% of the stock is owned by institutional investors and hedge funds.

About Alaunos Therapeutics

(Get Free Report)

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.